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Objective: To determine whether ethnic-specific differences in 
the prevalence of cardiovascular risk factors and outcomes exist 
worldwide among individuals with stable arterial disease.
Patients and MethOds: From December 1, 2003, to June 30, 
2004, the prospective, observational REduction of Atherothrom-
bosis for Continued Health (REACH) Registry enrolled 49,602 out-
patients with coronary artery disease, cerebrovascular disease, 
and/or peripheral arterial disease from 7 predefined ethnic/racial 
groups: white, Hispanic, East Asian, South Asian, Other Asian, 
black, and Other (comprising any race distinct from those speci-
fied). The baseline demographic and risk factor profiles, medica-
tion use, and 2-year cardiovascular outcomes were assessed 
among these groups. 
Results: The prevalence of traditional atherothrombotic risk fac-
tors varied significantly among the ethnic/racial groups. The use 
of medical therapies to reduce risk was comparable among all 
groups. At 2-year follow-up, the rate of cardiovascular death was 
significantly higher in blacks (6.1%) compared with all other eth-
nic/racial groups (3.9%; P=.01). Cardiovascular death rates were 
significantly lower in all 3 Asian ethnic/racial groups (overall, 
2.1%) compared with the other groups (4.5%; P<.001).  
cOnclusiOn: The REACH Registry, a large international study 
of individuals with atherothrombotic disease, documents the im-
portant ethnic-specific differences in cardiovascular risk factors 
and variations in cardiovascular mortality that currently exist 
worldwide.
Mayo Clin Proc. 2011;86(10):960-967
BMI = body mass index; CAD = coronary artery disease; CVD = cerebro-
vascular disease; MI = myocardial infarction; PAD = peripheral arterial 
disease; REACH = REduction of Atherothrombosis for Continued Health
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Atherothrombotic disease, which clinically manifests as coronary artery disease (CAD), peripheral arterial dis-
ease (PAD), and cerebrovascular disease (CVD), is a leading 
cause of morbidity and mortality worldwide. Despite estab-
lished management guidelines, contemporary data indicate 
that undertreatment of risk factors and underuse of proven 
medical therapies in the treatment of atherothrombotic dis-
ease continue to be significant globally.1 Although the use of 
evidence-based therapies, including lifestyle interventions 
and pharmacotherapies, has been shown to improve patient 
outcomes, individuals with CAD, PAD, and CVD continue 
to have considerably high rates of adverse ischemic events.2 
The clinical and socioeconomic implications of this disabling 
disease will only intensify as the prevalence of atherothrom-
botic disease continues to increase worldwide.
 The natural history, prevalence, and individual risks 
for the disease subsets encompassed by atherothrombo-
sis vary by ethnicity.3-5 Ethnicity has been shown to be an 
independent predictor of various adverse cardiovascular 
outcomes in patients with atherothrombotic disease, in-
cluding cardiovascular and all-cause mortality.6 Ethnic-
specific variations in the treatment of atherothrombotic 
disease have been demonstrated despite adjustments 
accounting for risk factor variations, differences in ac-
cess to care, adherence to medical therapies, and other 
socioeconomic factors.7 However, the majority of previ-
ous data examining ethnicity and its impact in athero-
thrombotic disease have come from single regional stud-
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ies limited in their geographic scope and their extent of 
ethnic diversity.
 The international, prospective, observational REduc-
tion of Atherothrombosis for Continued Health (REACH) 
Registry is designed to evaluate those at risk for or with 
established atherothrombotic disease from highly diverse 
ethnic populations worldwide. The registry assessed the 
cardiovascular risk profiles, treatment regimens, and out-
comes of nearly 68,000 outpatients enrolled in 44 coun-
tries. In the current study, we evaluate those individuals 
with symptomatic atherothrombotic disease (CAD, PAD, 
and/or CVD) and assess baseline demographic risk pro-
files, medication profiles, and 2-year cardiovascular event 
rates according to ethnicity.
PATIENTS AND METHODS
A detailed description of the study design, methodol-
ogy, and baseline characteristics of individuals enrolled 
in the international, prospective REACH Registry has 
been previously reported.1,8 Briefly, the registry included 
outpatients aged 45 years or older with either established 
atherothrombotic disease (CAD, PAD, or CVD) or 3 or 
more cardiovascular risk factors from 5587 practices in 
44 countries. Study participants were enrolled from De-
cember 1, 2003, to June 30, 2004 (except in Japan, where 
an enrollment delay resulted from regulatory require-
ments), and had an anticipated clinical follow-up of 2 
years. Investigators submitted this protocol to the insti-
tutional review boards in each country according to local 
requirements, and all participants were required to sign 
informed consent.
 The current study included only those individu-
als with symptomatic atherothrombotic disease (CAD, 
PAD, and/or CVD). Ethnicity was self-reported, and 
participants were instructed to choose one of the follow-
ing 7 predefined ethnic/racial groups: white, Hispanic, 
East Asian, South Asian, Other Asian, black, or Other. 
Mixed-race individuals were asked to identify them-
selves by the racial subgroup that they thought had the 
greatest personal influence. Entry criteria for the study 
definitions of CAD, PAD, and CVD have been previous-
ly published.8 Established CAD was defined as one or 
more of the following: history of myocardial infarction 
(MI), history of coronary revascularization (percutane-
ous or surgical), or history of stable or unstable angina 
with documented CAD. Documented PAD included one 
or both of the following criteria: intermittent claudica-
tion with a documented ankle-brachial index less than 
0.9 or a prior related peripheral revascularization pro-
cedure (angioplasty, bypass grafting surgery, or amputa-
tion). To fulfill the criteria for documented CVD, indi-
viduals had to have a history of transient ischemic attack 
and/or ischemic stroke.
 On initial study enrollment, baseline data including ath-
erosclerotic risk factors and pharmacologic therapies were 
obtained from the individual medical records at each physi-
cian practice. Smoking status was subclassified into either 
current, former, or never. Current smoking was defined as a 
mean of at least 5 cigarettes per day within the past month 
before enrollment, whereas former smoking was defined as 
having smoked an average of at least 5 cigarettes per day 
but stopping more than a month before enrollment. Body 
mass index (BMI) was calculated by dividing weight (kg) 
by height (m2). Employment status was subdivided into 
full-time, part-time, unemployed, retired, and incapaci-
tated. The proportion of individuals within the target level 
baseline blood pressure (<130/80 mm Hg), fasting blood 
glucose (<110 mg/dL; to convert to mmol/L, multiply by 
0.0555), and fasting cholesterol (<175 mg/dL; to convert 
to mmol/L, multiply by 0.0259) measurements was used as 
an assessment of treatment efficacy.
Follow-up
Data regarding patient clinical outcomes were obtained 
from participating physicians at 2 years. Cardiovascular 
death included fatal MI, fatal stroke, and other cardiovascu-
lar death. Other cardiovascular death included other deaths 
of cardiac origin, pulmonary embolism, death due to heart 
failure, death after a vascular intervention or operation, and 
any observed or unobserved sudden death (unless identi-
fied as noncardiovascular in origin by autopsy). A death 
within 28 days of an MI or stroke was considered a fatal MI 
or fatal stroke, respectively.
StatiStical analySeS
Continuous variables and categorical variables are ex-
pressed as mean ± SD and frequencies or percentages, re-
spectively. Event rates are reported as 2-year event rates 
after adjustments for age, sex, enrolling country, type of en-
rolling physician, PAD, CAD, and CVD. Cumulative event 
rates were generated using the corrected group prognosis 
method.9 This method provides an alternative form for es-
timating survival rates from the Cox proportional hazards 
model. Event rates are reported only for those individuals 
with complete outcome and covariate information for the 
particular end point. Two-sided P values were considered 
significant when probability is <.05. Statistical analysis was 
performed using SAS version 8 (SAS Institute, Cary, NC).
RESULTS
Overall, 49,602 outpatients in the REACH Registry with 
established atherothrombotic disease at baseline were 
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included in this analysis. At 2 years, 45,191 individuals 
(91%) were available for follow-up. A total of 747 partici-
pants (1.5%) died within the first 2 years, and 3664 (7%) 
were lost to follow-up at 2 years. The rate of lost to follow-
up varied among the ethnic/racial groups: from 3% in East 
Asians to 16% in blacks. Baseline demographics, includ-
ing atherosclerotic disease, risk factors, and employment 
status, are listed in Table 1. Overall, 44% (14,709/33,588) 
of whites in the registry were enrolled in the United States, 
whereas 95% (1655/1748) of blacks were from the United 
States. Most Other Asians were enrolled from the Philip-
pines (30%; 796/2655), Thailand (15%; 411/2655), and 
Indonesia (15%; 400/2655). Hispanic enrollment was pre-
dominantly from the United States (36%; 819/2258), Mex-
ico (31%; 690/2258), and Spain (11%; 239/2258).
 There were significant differences among the ethnic/ra-
cial groups in each of the characteristics analyzed. The larg-
est category of atherothrombotic disease within each group 
was CAD, followed by CVD and lastly PAD. The rates of 
CAD varied significantly from a low of 51.4% in blacks to 
a high of 80.4% in South Asians (P<.001). Rates of CVD 
ranged from as low as 24.1% in South Asians to a high of 
46.2% in blacks (P<.001). The Asian populations had the 
lowest rates of PAD, with rates of 12.2% in Other Asians, 
13.0% in East Asians, and 13.3% in South Asians. Hispanics 
had the highest rate of PAD at 21.0% (P<.001).
 A large proportion of individuals within each ethnic/
racial group had traditional risk factors for atherothrom-
bosis, including diabetes mellitus, hypertension, and 
hyperlipidemia. Rates for each of these risk factors var-
ied significantly across the groups (P<.001 for all 3 risk 
factors), which is similar to the results seen in the full 
REACH Registry cohort of individuals with asymptom-
atic and symptomatic disease.1 Blacks had the highest 
rate of hypertension (93.0%), followed by East Asians 
(84.1%) and South Asians (83.7%). The highest rates of 
diabetes mellitus were seen in South Asians, blacks, and 
Hispanics, with rates of 57.9%, 55.0%, and 53.3%, re-
spectively. Whites had the lowest rates of diabetes mel-
litus (38.8%) and hypertension (79.1%), whereas blacks 
had the lowest rate of hyperlipidemia (51.4%). Most in-
dividuals were overweight and current or former smok-
ers. Overall, the average BMI within each ethnic/racial 
group fulfilled the criterion for a diagnosis of being over- 
weight (BMI ≥25 kg/m2), with the exception of East Asians, 
whose average BMI was 24.7 kg/m2. Despite having the 
second lowest mean BMI (25.4 kg/m2), South Asians had 
the highest rate of diabetes mellitus. Significant propor-
tions of registry participants in each ethnic/racial group 
were not working full-time but rather were retired, un-
employed, working part-time, or incapacitated. Full-time 
employment rates ranged from a low of 11.9% in whites 
to a high of 19.3% in South Asians (P<.001).
 Medication use at the time of study enrollment is listed 
in Table 2. The use of antiplatelet therapies, aspirin, and 
statins was similar among all ethnic/racial groups (Figure 
1). Nearly 70% of registry participants in each group were 
taking aspirin at baseline. The percentage of individuals 
within each group taking statins ranged from 57% to 68%. 
Overall use of statins in this population of individuals 
with established atherothrombotic disease was less than 
optimal, given that 50% or more of all individuals in each 
table 1. Baseline Characteristics of Patients With Atherothrombotic Disease in the REACH Registry by Ethnicity/Race
  Whites Hispanics East Asians South Asians Other Asians Blacks Others 
  (n=33,588) (n=2258) (n=7234) (n=542) (n=2655) (n=1748) (n=1577) P value
Age (y), mean ± SD 67.8±31.2 66.3±14.5 67.1±30.7 65.2±10.6 66.1±16.3 64.6±12.2 67.4±12.0 <.001
Men, % 67.6 64.5 67.8 73.8 70.1 55.3 68.1 <.001
Diabetes, % 38.8 53.3 50.8 57.9 49.3 55.0 42.7 <.001
Hypertension, % 79.1 80.3 84.1 83.7 82.8 93.0 80.7 <.001
Hyperlipidemia, % 60.1 56.6 63.2 61.4 62.6 51.4 64.7 <.001
Smoking status, % 
 Current 18.1 13.5 13.2 10.9 14.3 20.3 18.1 <.001
 Former 43.8 37.3 26.9 23.6 32.9 38.2 40.8 <.001
BMI (kg/m2), mean ± SD 27.3±16.4 27.6±7.6 24.7±16.2 25.4±5.6 25.6±8.6 28.9±6.4 27.4±6.3 <.001
Prior history of atherosclerotic disease, %
 CAD 68.9 66.4 69.4 80.4 64.3 51.4 68.8 <.001
 CVD 33.0 32.2 34.8 24.1 39.4 46.2 34.3 <.001
 PAD 19.1 21.0 13.0 13.3 12.2 20.7 20.6 <.001
 ABI <0.9 46.2 50.4 50.9 54.0 39.7 41.7 40.7 .26
 Asymptomatic carotid stenosis ≥70%   5.7   5.9   7.0   2.2   5.4   3.0   8.5 <.001
Employment status, %        
 Full-time 11.9 12.2 15.8 19.3 14.8 12.3 12.1 <.001
 Part-time   7.2   6.5   6.4   7.2   8.4   6.3   5.6 .22
 Unemployed   5.3 10.9   7.5   7.8   6.1   7.9   7.4 <.001
 Incapacitated   4.2   7.3   6.1   6.2   6.4   9.6   3.5 <.001
 Retired 58.2 51.1 50.1 44.4 50.0 48.6 57.9 <.001
For all presented variables, data were missing for less than 5% of each ethnicity/race category. ABI = ankle-brachial index; BMI = body mass index; CAD = coronary 
artery disease; CVD = cerebrovascular disease; PAD = peripheral arterial disease; REACH = REduction of Atherothrombosis for Continued Health.
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ethnic/racial group had a total cholesterol level of 175 mg/
dL or higher at baseline (Figure 2). The proportion of in-
dividuals with inadequately controlled blood pressure at 
study enrollment, which varied significantly among the 
groups, was highest in blacks (86%) (Figure 2). However, 
a large number of participants among the other ethnic/ra-
cial groups also had poorly controlled blood pressure at 
baseline, with rates ranging from 77% in whites to 84% 
in Hispanics (P<.001).
 The adjusted 2-year cardiovascular event rates are list-
ed in Table 3. The all-cause mortality rate for the overall 
population was 6.2%, and the cardiovascular death rate 
FiGuRe 1. Medication use among patients with atherothrombotic disease in the Reduction of atherothrombosis for continued health (Reach) 
Registry by ethnicity. ace-i = angiotensin-converting enzyme inhibitor.
table 2. Medication Use Among Patients With Atherothrombotic Disease in the REACH Registry by Ethnicity/Race
  Whites Hispanics East Asians South Asians Other Asians Blacks Others 
  (n=33,588) (n=2258) (n=7234) (n=542) (n=2655) (n=1748) (n=1577) P value
Antihypertensive drugs, %       
	 β-Blockers 39 37 43 42 41 40 38 .25
 ACE-inhibitors 43 46 36 42 41 51 44 <.001
 Diuretics 37 34 35 31 33 51 39 <.001
 CCBs 35 34 35 37 40 50 34 <.001
 ARBs 15 16 24 20 19 20 15 <.001
 Other antihypertensives 7 8 10 5 8 11 8 <.001
Anticoagulants, %        
 ≥1 antiplatelet agent 86 86 88 89 88 86 85 .34
 Acetylsalicylic acid 70 69 70 72 72 67 70 .41
 Other antiplatelet agent 30 35 37 37 31 34 27 <.001
 Other anticoagulants 13 9 9 8 8 10 14 <.001
Diabetic agents, %        
 Sulfonylureas 14 23 21 28 23 20 17 <.001
 Biguanides 12 20 18 21 18 16 15 <.001
 Insulin 11 17 11 15 9 21 11 <.001
 Thiazolidinediones 1 2 2 2 1 1 1 <.001
 Other diabetic agent 1 1 2 1 2 1 1 <.001
Analgesics, %        
 Nitrates 16 20 17 13 14 21 19 <.001
 NSAIDs 4 5 6 4 6 5 5 .01
Lipid-lowering therapy, % 66 64 71 69 70 58 69 .13
 Statins 61 60 68 65 66 57 62 .45
 Other lipid-lowering agent 7 5 6 6 5 4 5 <.001
For all presented variables, data were missing for less than 5% of each ethnicity/race category. ACE = angiotensin-converting enzyme; ARBs = 
angiotensin II receptor antagonists; CCBs = calcium channel blockers; NSAIDs = nonsteroidal anti-inflammatory drugs; REACH = REduction of 
Atherothrombosis for Continued Health.
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FiGuRe 2. undertreatment of risk factors among patients with atherothrombotic disease in the Reduction of atherothrombosis for continued 
health (Reach) Registry by ethnicity. si conversion factor: to convert cholesterol value to mmol/l, multiply by 0.0259.
was 4.0%. There were significant differences in both all-
cause and cardiovascular mortality among the ethnic/
racial groups. Mortality rates were consistently lower in 
all 3 Asian populations (East, South, and Other Asians), 
whereas rates were uniformly higher in blacks. Blacks 
had a significantly higher cardiovascular death rate com-
pared with all other ethnic/racial groups (6.1% vs 3.9%, 
respectively; P=.01). East Asians, South Asians, and Other 
Asians had significantly lower cardiovascular death rates of 
1.8%, 1.9%, and 2.2%, respectively (all Asians combined, 
2.1% vs 4.5%; P<.001). There were no significant differ-
ences among the groups in the rates of nonfatal MI, or the 
composite end point of cardiovascular death, MI, stroke, 
or hospitalization for an atherothrombotic event. Nonfatal 
stroke rates were lowest in Asians and highest in blacks, 
although this difference was not significant (P=.05).
 Data on other secondary cardiovascular outcomes 
resulting in hospitalizations are provided in Table 4. 
table 3. Adjusted 2-Year Major Cardiovascular Event Rates Among Patients With Atherothrombotic Disease  
in the REACH Registry by Ethnicity/Racea
  Total Whites Hispanics East Asians South Asians Other Asians Blacks Others P value
  (N=49,602) (n=33,588) (n=2258) (n=7234) (n=542) (n=2655) (n=1748) (n=1577) 
All-cause mortality, % 6.2 7.0 5.5 3.1 3.2 3.9 8.1 6.0 .04
 (95% CI) (4.8-7.7) (4.9-9.0) (3.3-7.6) (1.5-4.7) (1.1-5.1) (2.0-5.6) (4.8-11.1) (4.8-7.6) 
CV death, % 4.0 4.5 3.6 1.8b 1.9b 2.2b 6.1c 3.7 .03
 (95% CI) (2.8-5.1) (2.7-6.1) (1.8-5.3) (0.6-3.0) (0.4-3.4) (0.9-3.5) (3.0-9.1) (1.9-5.5) 
Nonfatal MI, % 3.3 3.2 3.6 3.9 2.9 3.8 3.3 2.9 .64
 (95% CI) (2.2-4.3) (2.1-4.3) (1.9-5.2) (1.0-6.6) (0.9-4.8) (1.7-5.8) (1.7-4.9) (1.5-4.3) 
Nonfatal stroke, % 3.7 4.0 3.9 2.8 2.4 2.8 5.7 3.9 .05
 (95% CI) (2.6-4.8) (2.4-5.6) (1.8-5.8) (1.2-4.3) (0.5-4.2) (1.2-4.4) (3.0-8.2) (2.0-5.8) 
CV death, MI, stroke, % 8.8 9.3 8.7 7.4 6.3 6.9 11.2 8.3 .08
 (95% CI) (7.1-10.5) (7.0-11.4) (5.9-11.3) (3.9-10.6) (3.3-9.2) (4.4-9.3) (7.9-14.3) (5.7-10.7) 
CV death, MI, stroke, or 
 hospitalization for an event, % 20.2 19.6 20.1 23.1 19.1 21.4 20.9 21.2 .13
 (95% CI) (18.0-22.2) (17.3-21.8) (16.7-23.2) (18.4-27.5) (14.3-23.5) (17.4-25.1) (17.6-23.9) (17.9-24.4) 
a Event rates were calculated using the corrected group prognosis method, adjusting for age, sex, enrolling country, type of enrolling physicians, PAD, CAD, 
and CVD; due to missing covariate data, the number of individuals included in these analyses was 49,003 in total (33,140 whites, 2220 Hispanics, 7223 
East Asians, 539 South Asians, 2646 Other Asians, 1669 blacks, and 1566 Others). CAD = coronary artery disease; CI = confidence interval; CV = cardio-
vascular; CVD = cerebrovascular disease; MI = myocardial infarction; PAD = peripheral arterial disease; REACH = REduction of Atherothrombosis for 
Continued Health. 
b P<.001 for all Asians vs all other ethnic groups.
c P=.01 for blacks vs all other ethnic groups.
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Although the overall rates of cardiovascular revascular-
ization procedures were similar among the ethnic/racial 
groups, there were significant differences in the rates 
of carotid and peripheral revascularization procedures. 
The rates of carotid angioplasty or stenting and carotid 
surgery were nearly twice as high in Other Asians (1.4% 
and 2.1%, respectively) compared with the other ethnic/
racial groups. The rate of peripheral artery bypass graft 
surgery was also highest in the Other Asian population 
(2.6%; P=.01); however, PAD angioplasty or stenting 
and amputation rates were similar among the groups. 
Despite having higher rates of hospitalization due to 
carotid and peripheral revascularization procedures, 
Other Asians were among the groups with the lowest 
cardiovascular death rates and nonfatal stroke rates. In 
contrast, blacks, who tended to have the highest rates 
of hard cardiovascular outcomes (cardiovascular death, 
nonfatal stroke, and nonfatal MI), had similar or slightly 
lower rates of ischemic events resulting in hospitaliza-
tion and cardiovascular, cerebrovascular, or peripheral 
revascularization procedures.
DISCUSSION
The results of this wide-reaching, contemporary analysis 
composed of a markedly diverse population with stable 
CAD, CVD, and/or PAD demonstrate important ethnic-
specific variations in the risks, management, and out-
comes associated with atherothrombotic disease. Blacks 
with atherothrombotic disease, mainly comprising African 
Americans from the United States (95%), had the highest 
rate of cardiovascular death among the ethnic/racial groups 
worldwide. In contrast, Asians had significantly lower rates 
of both all-cause mortality and cardiovascular death. De-
spite being the ethnic/racial group with the largest propor-
tion of CAD, South Asians had one of the lowest rates of 
table 4. Two-Year Cardiovascular Surgery and Other Cardiovascular Event Rates Among Patients With  
Atherothrombotic Disease in the REACH Registry by Ethnicity/Racea
  Total Whites Hispanics East Asians South Asians Other Asians Blacks Others 
  (N=49,602) (n=33,588) (n=2258) (n=7234) (n=542) (n=2655) (n=1748) (n=1577) P value
Unstable angina, % 7.2 6.8 7.6 12.6 7.2 8.3 7.5 7.7 .001
 (95% CI) (5.9-8.6) (5.5-8.1) (5.4-9.7) (8.3-16.6) (4.0-10.2) (5.6-10.9) (5.5-9.5) (5.6-9.6) 
TIA, % 2.6 2.4 3.2 3.9 3.4 2.9 3.3 2.5 .14
 (95% CI) (1.8-3.4) (1.6-3.2) (1.6-4.7) (1.5-6.2) (0.8-5.9) (1.3-4.4) (1.8-4.7) (1.3-3.6) 
Other ischemic arterial 
 event, % 2.1 1.9 2.2 3.3 2.9 4.4 2.1 3.0 <.001
 (95% CI) (1.4-2.9) (1.2-2.6) (1.0-3.4) (1.0-5.5) (0.4-5.3) (2.1-6.7) (1.1-3.2) (1.6-4.3) 
Congestive heart 
 failure, % 5.7 5.3 5.6 6.6 9.6 7.0 7.7 7.4 <.001
 (95% CI) (4.5-6.9) (4.1-6.5) (3.8-7.4) (3.7-9.3) (5.3-13.6) (4.5-9.4) (5.5-9.8) (5.2-9.4) 
Bleeding 1.4 1.4 1.5 1.7 1.4 1.4 1.5 1.8 .96
 (95% CI) (0.8-2.1) (0.8-2.1) (0.6-2.5) (0.3-3.1) (0.0-2.8) (0.3-2.5) (0.6-2.4) (0.6-3.0) 
Worsening of 
 claudication and 
 hospitalization, % 4.8 4.8 4.1 4.9 5.5 6.0 5.3 4.3 .33
 (95% CI) (3.8-5.8) (3.7-5.9) (2.6-5.5) (2.2-7.3) (2.3-8.2) (3.6-8.2) (3.7-6.9) (2.9-5.5) 
New diagnosis of 
 claudication and 
 hospitalization, % 2.5 2.1 1.9 2.9 2.0 3.1 2.0 2.0 .62
 (95% CI) (1.7-3.3) (1.4-2.9) (0.8-2.9) (0.7-5.0) (0.2-3.8) (1.4-4.7) (1.0-3.1) (1.1-3.0) 
Coronary angioplasty 
 or stenting, % 4.5 4.3 4.7 5.7 4.4 4.6 3.6 5.1 .45
 (95% CI) (3.4-5.6) (3.2-5.4) (3.0-6.5) (3.1-8.2) (2.1-6.6) (2.6-6.6) (2.3-5.0) (3.3-6.9) 
CABG, % 1.6 1.6 2.7 1.8 1.0 1.8 1.5 1.6 .14
 (95% CI) (1.0-2.3) (0.9-2.3) (1.1-4.2) (0.4-3.3) (0.0-1.9) (0.5-3.0) (0.6-2.4) (0.6-2.6) 
Carotid angioplasty 
 or stenting, % 0.50 0.5 0.6 0.5 0.3 1.4 0.1 0.4 .02
 (95% CI) (0.2-0.8) (0.2-0.9) (0.1-1.2) (0.0-1.2) (0.0-0.9) (0.2-2.7) (0.0-0.3) (0.0-0.8) 
Carotid surgery, % 0.7 0.7 0.7 0.1 1.3 2.1 0.4 0.8 .001
 (95% CI) (0.3-1.1) (0.3-1.2) (0.1-1.3) (0.0-0.4) (0.0-3.1) (0.4-4.0) (0.1-0.8) (0.2-1.6) 
Peripheral artery 
 bypass grafting, % 1.1 1.0 1.5 1.7 1.4 2.6 0.7 1.0 .01
 (95% CI) (0.6-1.6) (0.5-1.5) (0.5-2.4) (0.0-3.4) (0.0-2.9) (0.8-4.3) (0.2-1.3) (0.3-1.6) 
PAD angioplasty 
 or stenting, % 1.7 1.8 1.5 1.9 1.3 1.5 1.6 1.5 .87
 (95% CI) (1.1-2.3) (1.1-2.4) (0.6-2.4) (0.2-3.5) (0.0-2.6) (0.4-2.6) (0.7-2.4) (0.7-2.2) 
Amputation, % 0.6 0.5 0.5 0.9 0.4 1.2 0.7 0.6 .31
 (95% CI) (0.2-1.0) (0.2-0.9) (0.1-1.0) (0.0-1.9) (0.0-1.0) (0.1-2.3) (0.1-1.3) (0.1-1.1) 
a Event rates were calculated using the corrected group prognosis method, adjusting for age, sex, enrolling country, type of enrolling physicians, PAD, CAD, 
and CVD; due to missing covariate data, the number of individuals included in these analyses was 49,003 in total (33,140 whites, 2220 Hispanics, 7223 East 
Asians, 539 South Asians, 2646 Other Asians, 1669 blacks, and 1566 Others). CABG = coronary artery bypass graft surgery; CAD = coronary artery disease; 
CI = confidence interval; CVD = cerebrovascular disease; PAD = peripheral arterial disease; REACH = REduction of Atherothrombosis for Continued Health; 
TIA = transient ischemic attack.
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MI seen at 2 years, with no apparent explanation. Nonfatal 
stroke rates were uniformly lower in Asians compared with 
the other groups. Overall, all hard cardiovascular events 
tended to be higher in blacks and lower in South Asians, 
East Asians, and Other Asians (largely composed of Asians 
from the Philippines, Thailand, and Indonesia).
 Traditional atherosclerotic risk factors varied with eth-
nicity/race, as did the rates of obesity, which have now 
risen to epidemic proportions on a global scale. Although 
obesity rates were uniformly lower in the Asian popula-
tions, this did not translate into lower rates of comorbid 
conditions such as diabetes mellitus—South Asians had 
the highest burden of diabetes mellitus. These findings are 
consistent with previous studies demonstrating variability 
in the amount of body fat per BMI and the subsequent pro-
pensity to develop cardiovascular risk factors, particularly 
diabetes mellitus, for a given BMI measurement among the 
various ethnic/racial groups, especially Asians.10-12
 The distribution of atherosclerotic disease also varied 
among the ethnic/racial groups. South Asians had a much 
higher rate of CAD with lower rates of CVD or PAD in 
comparison with the other groups. These findings confirm 
previously published data illustrating the increasingly high 
burden of CAD in the developing countries of South Asia.13 
Although blacks tended to have the greatest burden of tra-
ditional atherosclerotic risk factors, they had the smallest 
proportion of individuals with documented CAD; yet their 
rate of CVD was highest among the groups. Whether this 
denotes a difference in atherothrombotic disease predilec-
tion for certain vascular beds (ie, coronary, cerebrovascu-
lar, or peripheral) among individuals within various ethnic/
racial groups is unknown. It is conceivable that certain ath-
erosclerotic risk factors confer increased susceptibility to-
ward a particular disease subset. For example, the increased 
prevalence of hypertension, particularly uncontrolled and/
or undertreated hypertension as seen in the current study, 
within the black population may predispose them to having 
a cerebrovascular event (eg, stroke, transient ischemic at-
tack) as their initial clinical manifestation of atherothrom-
botic disease.
 The Clopidogrel for High Atherothrombotic Risk and 
Ischemic Stabilization, Management, and Avoidance 
(CHARISMA) study of approximately 15,000 patients 
with atherothrombosis found that blacks had significantly 
higher all-cause and cardiovascular mortality compared 
with Asian patients.6 Several prior studies have also dem-
onstrated ethnic disparities in the use and outcomes as-
sociated with coronary, cerebrovascular, and peripheral 
revascularization procedures.14-20 There were significant 
differences in the rates of specific cerebrovascular and pe-
ripheral revascularization procedures among the ethnic/ra-
cial groups in this cohort. Despite having one of the lowest 
rates of stroke, the Other Asian group was twice as likely to 
have undergone carotid angioplasty or stenting or carotid 
surgery within 2 years compared with the other groups. 
Rates of peripheral artery bypass graft surgery were also 
highest in Other Asians. Although blacks had consistent-
ly higher rates of hard cardiovascular events, the rates of 
carotid angioplasty, carotid surgery, and peripheral artery 
bypass grafting were among the lowest seen. There were 
no ethnic-specific variations in rates of coronary revascu-
larization procedures (angioplasty or stenting or coronary 
artery-bypass grafting).
 The current analysis provides a contemporary “real-
world” reflection of specific ethnic data from a large-
scale, extremely diverse population group with athero-
thrombotic disease with excellent 2-year follow-up rates 
given its geographic reach. Despite these facts, the article 
has limitations. Ethnicity was self-reported and required 
mixed-race individuals to choose only one identity. Fur-
thermore, despite best attempts to adequately adjust for 
confounding variables associated with ethnicity/race, such 
as the impact of geographic locale, access and delivery of 
primary and secondary medical care, physician practice 
preferences, and physician and patient beliefs, delineat-
ing their impact on our findings is difficult. Although the 
REACH Registry enrolled an extensively heterogeneous 
population, many important ethnic/racial groups are un-
derrepresented. Likewise, REACH is an observational, 
non–population based registry and, therefore, our find-
ings are vulnerable to criticism regarding their external 
validity. Medical compliance, including contraindications 
and financial hardship, was not recorded, and their effect 
on physician prescribing practices is unknown.
CONCLUSION
Our findings from this large global registry of individuals 
with atherothrombotic disease illustrate several important 
ethnic differences in treatment patterns and outcomes from 
the current era. In general, blacks (consisting mainly of Af-
rican Americans) had higher rates of adverse cardiovascu-
lar outcomes, with the highest rate of cardiovascular death 
among the groups. However, Asians had significantly lower 
rates of all-cause and cardiovascular death. The underly-
ing etiologies for these findings have yet to be defined and 
should be the focus of continued research endeavors in this 
area. Continued efforts are needed to establish the impact of 
specific social, cultural, and environmental factors among 
various ethnicities on health outcomes. Cooperative efforts 
from both physicians and the patients they treat to adhere 
to evidence-based risk factor and lifestyle modifications are 
paramount in efforts to eliminate any ethnic disparities in 
outcomes from this increasingly burdensome disease.
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